Scopolamine

An anticholinergic skin patch, FDA-approved in adults to prevent nausea and vomiting from motion sickness or after surgery and anesthesia.

psilodex.org/m/scopolamine · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~9.5 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Scopolamine”, v2026.10.05. psilodex.org/m/scopolamine

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

Nausea and vomiting from motion sickness (prevention)
Postoperative nausea and vomiting (prevention)

Sources [1]

Other safety

The label reports hyperthermia, including fatal cases, and acute angle-closure glaucoma; it is contraindicated in angle-closure glaucoma.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

Not studied with psilocybin; it can cause confusion and hallucinations, so added or blurred effects are possible.

Detail No psilocybin data exist for scopolamine. It is an anticholinergic (drying, confusing) drug that can itself cause drowsiness, confusion, hallucinations and agitation. These may add to or blur psilocybin's effects. Also, its label also reports seizures, and hyperthermia (overheating) with reduced sweating. It also reports withdrawal symptoms (dizziness, nausea, confusion, low blood pressure) after patch removal. Sources [1]

Human data with psilocybin: No psilocybin data; based on how it works and its label
Half-life: ~9.5 h (after patch removal) (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

5 listed · counted on reports

Anticholinergic: Blocks acetylcholine. Can cause a fast heart rate, dry mouth, reduced sweating and heat intolerance, and confusion, more so at high doses or in combination. Sources [1]
Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]
Withdrawal or rebound if stopped abruptly: Stopping suddenly can cause withdrawal or a rebound of symptoms. Sources [1]
Psychiatric reactions: The label or source warns of psychiatric effects such as psychosis, mania, hallucinations, suicidal thoughts or severe mood or behavior changes. Psilocybin can also bring up strong emotions, so these warnings are relevant to screening. Sources [1]
Lowers seizure threshold or carries seizure risk: Makes a seizure more likely, or has been linked to seizures. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

TRANSDERM SCŌP (scopolamine) transdermal system (Baxter) · FDA label (DailyMed) — Anticholinergic: 1 "TRANSDERM SCŌP is an anticholinergic indicated in adults for the prevention of:" | Psychiatric reactions: 5.2 "Scopolamine has been reported to exacerbate psychosis." | Lowers seizure threshold or carries seizure risk: 5.2 "Seizures and seizure-like activity have been reported in patients receiving scopolamine." | Sedating or CNS depressant: 5.2 "Scopolamine can cause drowsiness, disorientation, and confusion." | Withdrawal or rebound if stopped abruptly: 5.6 "Discontinuation of TRANSDERM SCŌP, usually after several days of use, may result in withdrawal symptoms" | 12.3 "Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours."

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →